STOCK TITAN

Akebia Therapeut - AKBA STOCK NEWS

Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.

Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical leader developing innovative therapies for kidney disease, including FDA-approved Auryxia® and investigational oral HIF inhibitor Vafseo™. This page provides authorized updates on clinical developments, regulatory milestones, and strategic initiatives shaping renal care.

Access Akebia's official press releases covering phase 3 trial results, regulatory submissions, and commercial partnerships with dialysis providers. Investors will find timely updates on financial performance, including earnings calls and SEC filings related to anemia treatment innovations.

Our curated news collection helps stakeholders track progress in HIF biology applications and chronic kidney disease management. Bookmark this page for verified updates on product approvals, research collaborations, and market expansion strategies directly from Akebia Therapeutics.

Rhea-AI Summary
Akebia Therapeutics granted options to purchase 2,000 shares of common stock to a newly-hired employee. The options have an exercise price of $1.14 per share and vest over four years. Each option has a 10-year term.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
none
-
Rhea-AI Summary
Akebia Therapeutics has resubmitted its New Drug Application to the FDA for vadadustat, an oral treatment for anemia due to chronic kidney disease. The resubmission includes post-marketing safety data from Japan. A letter from the FDA acknowledging the resubmission is expected in 30 days, with a PDUFA date set for six months from submission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
none
-
Rhea-AI Summary
Akebia Therapeutics receives approval for Vafseo in Australia for the treatment of anemia in CKD patients on dialysis. Vadadustat achieved primary and secondary efficacy endpoints in clinical trials. Akebia plans to resubmit new drug application for vadadustat in the US. Akebia appoints Graham Ray as VP to lead customer engagement. Auryxia net product revenue guidance slightly lowered to $170-$175 million for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
none
Rhea-AI Summary
Akebia Therapeutics, Inc. (Nasdaq: AKBA) will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11, 2023. The conference will be held in New York from September 11-13, 2023. The webcast of the presentation can be accessed through Akebia's website, with a replay available for approximately 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
conferences
-
Rhea-AI Summary
Akebia Therapeutics grants options to newly-hired employees as inducements
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
none
-
Rhea-AI Summary
Akebia reports Q2 2023 net product revenue of $42.2 million for Auryxia and reaffirms 2023 revenue guidance of $175.0-$180.0 million. Plans to resubmit NDA for vadadustat in Q3 2023. Akebia gains approval for vadadustat in 33 additional countries. Akebia enters exclusive license agreement with Medice. Net loss of $11.2 million for Q2 2023. Cash position of $53.6 million as of June 30, 2023. Akebia identifies accounting errors and material weakness in internal controls.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
Rhea-AI Summary
Akebia expects to resubmit NDA for vadadustat by Q3 2023, received productive meeting minutes with FDA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
-
Rhea-AI Summary
Akebia to release Q2 financial results on August 25th and host conference call at 9:00 a.m. ET
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
conferences earnings
-
Rhea-AI Summary
Akebia Therapeutics, Inc. received a notice of non-compliance from Nasdaq for not timely filing its Form 10-Q. The company plans to release its financial results for Q2 2023 by August 25, 2023, and expects to regain compliance upon filing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.29%
Tags
none
Akebia Therapeut

Nasdaq:AKBA

AKBA Rankings

AKBA Stock Data

538.14M
232.73M
4.45%
28.9%
6.82%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CAMBRIDGE